Navigation Links
Shire Continues to Deliver Excellent Growth From Core Products
Date:10/30/2009

MS Data not available. (5) Not sold in the US. Specialty Pharmaceuticals US ADHD market share

Shire's share of the total US ADHD market for the three months to September 30, 2009 was 22%. Shire continues to have the leading portfolio of branded products in the US ADHD market.

VYVANSE - ADHD

Product sales of VYVANSE for the three months to September 30, 2009 increased by 34% to $129.0 million (2008: $96.0 million), with VYVANSE's average share of the US ADHD market for Q3 2009 increasing to 13% (2008: 9%). Product sales growth was driven by a 57% increase in US prescription demand in Q3 2009 over the same period in 2008, as a result of increased average market share and 10% growth in the US ADHD market. Product sales growth was less than prescription growth due to the stocking benefits from new dosage strengths of VYVANSE in Q3 2008.

ADDERALL XR - ADHD

Product sales of ADDERALL XR for the three months to September 30, 2009 were $70.9 million (2008: $268.7 million), a decrease of 74%, following the launch by Teva in April 2009 of its authorized generic version of ADDERALL XR. The launch of the authorized generic version led to a 59% decline in ADDERALL XR US prescription demand and higher US sales deductions in Q3 2009 than the same period last year.

Sales deductions represented 73% of branded ADDERALL XR gross sales in Q3 2009, compared to 26% in the same period in 2008 following higher Medicaid and Managed Care rebates subsequent to generic launch. These factors more than offset the positive impacts of price increases taken since Q3 2008, and the inclusion in product sales of shipments of authorized generic ADDERALL XR to Teva and Impax Laboratories, Inc. ("Impax") in Q3 2009.

US oral mesalamine market share

Shire's average market share of the US oral mesalamine market was 33% for the three months to September 30, 2009.


'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 /CNW/ - On Aug. 20, at its annual ... Medical Association (CMA) voted on and approved a delegate ... medicinal cannabis. Bedrocan Cannabis Corp., a leading Canadian licensed ... motion. The CMA is quite right to ... smoking any plant material, including medicinal cannabis. While some ...
(Date:8/22/2014)... , Aug. 22, 2014  Dr. Mark ... with the Diamond Lifetime Achievement Award in the field ... CEO of Cardiovascular Clinical Associates. Dr. Rasak ... managing all major aspects of the business; overseeing the ... as primary coronary intervention. In addition, he is an ...
(Date:8/22/2014)... Research and Markets has announced ... Catheter Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Global and Chinese Intravenous Catheter Industry Report 2014 2
... 23, 2007 /PRNewswire-FirstCall/ -- Shire plc,announced that ... non-oral medication approved for treatment of,Attention Deficit ... 12 years, provided significant improvement in symptom ... 12-month open-label,study presented at the American Psychiatric ...
... WIRE)--May 24, 2007 - Inovio Biomedical,Corporation (AMEX:INO), ... for cancers and infectious diseases and a ... announced today,that interim clinical trial results demonstrated ... technology was,safe and tolerable, facilitated gene expression, ...
Cached Medicine Technology:12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 212-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 312-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 412-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 512-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 612-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 712-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 812-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 9Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 2Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 3Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 4Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 5
(Date:8/22/2014)... The regional economy is about to ... on the grow again. The plant will invest ... to boost production of the popular Highlander midsize sport ... investment to $4 billion. This step allows Toyota to ... flexibility to adjust its product mix to meet changing ...
(Date:8/22/2014)... News) -- Many Americans know little about how Ebola is ... outbreak in the United States, a new survey shows. ... there will be a major Ebola outbreak in the United ... family member will get sick with the deadly virus in ... Public Health poll. However, those opinions don,t match reality, ...
(Date:8/22/2014)... August 22, 2014 Beat Eczema ... they can use natural methods to completely cure the ... the attention of Shane Michaels, prompting an investigative review. ... affects the skin, it can still be extremely debilitating ... Michaels. “The intense itching and pain that it causes ...
(Date:8/22/2014)... (EGFR) mutations found in the circulating free tumor DNA ... cancer (NSCLC) patients correlates well with the EGFR mutations ... inhibitor (TKI) therapy is approved for EGFR activating mutation ... determining mutation status is with DNA derived directly from ... A more abundant and less invasive source of tumor ...
(Date:8/22/2014)... London, UK (PRWEB) August 22, 2014 ... more magnetic for some clinical applications due to ... of the emerging innovations in ultrasound, such as ... imaging, are expected to keep the market moving ... as increasing mobility can enhance not only the ...
Breaking Medicine News(10 mins):Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3
... New studies at the University of Adelaide, Australia, will delve ... tumours and stroke. , The research, to be conducted in ... aim to find links between chemical signals in the brain ... , There are still many mysteries around how the brain ...
... Perfect" Score by the American Correctional Association Auditors ... Earns High Praise From Board Chair Romanowicz, ... an exhaustive,three-day audit and examination by the American Correctional ... pleased to report that the Donald W. Wyatt Detention,Facility ...
... Companies align,commercial and portfolio management employees by therapeutic ... of $10 to 20 billion, on average nine,marketing ... along,with approximately eight portfolio managers. At companies with ... three, commercial to,portfolio management staff, according to a ...
... and Other Ethnic Minorities at Increased Risk, BALTIMORE, ... J.,Barthelow Classen in The Open Endocrinology Journal shows a ... following the,discontinuation of a single vaccine, a vaccine to ... is a global epidemic of type 2,diabetes and metabolic ...
... are five-to-six times more likely to be at serious risk ... early as their teenage years, according to a new study ... Hill. , The findings, published Friday (April 4) in the ... children twice first while in grade school, then again ...
... at Ralphs Pharmacies Throughout Southern California, LOS ANGELES, ... pharmacy customers generic drugs for $4 per prescription at,its ... apply to hundreds of generic drugs prescribed for,30-day supplies ... stores,throughout Southern California. A list of the participating pharmacies ...
Cached Medicine News:Health News:Unlocking mysteries of brain cancer, stroke 2Health News:Donald W. Wyatt Detention Facility Scores 3-Year Accreditation and Among Highest Rated in the United States 2Health News:Donald W. Wyatt Detention Facility Scores 3-Year Accreditation and Among Highest Rated in the United States 3Health News:Early-stage Commercialization Success: Pharma Companies Adjust Resources in Light of Industry Changes 2Health News:Vaccine Induced Inflammation Linked to Epidemic of Type 2 Diabetes and Metabolic Syndrome 2Health News:Inactive kids face 6-fold risk of heart disease by teen years, study finds 2Health News:Ralphs Introduces $4 Generic Drugs 2
... on patented microplate agglutination technology. Its is ... donor ABO/Rh testing. PK7200 also handles weak ... antibody detection. The Automated Microplate System delivers ... proven reliability that for the past generation ...
... Tecan Haemotyper is an automated ... The Tecan Haemotyper combines a ... platform with the DiaMed agglutination ... process DiaMed-ID cards and microplates ...
... 1990s, the "Reversed" shoulder prosthesis has been ... success. More recently, an ever-growing number of ... to champion this prosthesis and the associated ... reversed technology is the result of nearly ...
Inquire...
Medicine Products: